Business
SOPHiA GENETICS Announces Three Poster Presentations and One Online Publication Accepted at the 2022 American Society of Clinical Oncology Annual (ASCO) Meeting
BOSTON and LAUSANNE, Switzerland, June 1, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced three
About this update from Sophia Genetics Sa
[{"type":"text","content":"BOSTON and LAUSANNE, Switzerland, June 1, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced three abstracts accepted for poster presentation and one for online publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago. SOPHiA GENETICS and GE Healthcare will also be hosting an Innovation Symposium on Monday, June 6th from 6:30 – 8:00 pm to present how the companies are working together to deliver on the promise of integrated cancer medicine by bringing global insights across multiple diagnostic modalities to clinical and biopharma customers.\n\n \n \n \n \n \n \n\n \n\"These high-impact ASCO contributions from SOPHiA GENETICS and collaborators demonstrate how our multimodal technology and solutions help drive novel insights and enhance oncology discoveries,\" said Dr. Philippe Menu, Chief Medical Officer at SOPHiA GENETICS. \"By utilizing our data-driven medicine approach and by applying our AI and machine learning algorithms to real-world multimodal data sets, SOPHiA GENETICS has the potential to help inform treatment decisions at the individual patient level for cancer patients globally. I am really excited to attend ASCO to share how our mission to democratize data-driven medicine is helping transform cancer care.\"\nAn overview of the four accepted SOPHiA GENETICS abstracts at ASCO 2022 are included below. The full abstracts will be published in the Meeting Proceedings, an online supplement of the Journal of Clinical Oncology.\nIndividualized prediction of post-surgical pathologic T3a (pT3a) upstaging risk in localized renal tumors undergoing nephrectomy (UroCCR 15 study) (Abstract # 4547, Poster # 38)Overview: UroCCR is a French national network of 37 multidisciplinary teams for kidney cancer management that collects longitudinal data on the routine clinical care of its patients. For the study, a retrospective cohort of 4,395 cases of clinical T1-T2 kidney tumors was analyzed. The study suggests that machine learning applied to pre-surgical multimodal data can predict the risk of pT3a upstaging of a localized kidney tumor and inform long-term outcomes at the individual patient level. The results have been validated on an external cohort of 1,759 patients with data from the clinical routine.This abstract has been ac...